Lupin licenses NeuClone's cell line as it builds biologics interests
This article was originally published in Scrip
Executive Summary
Lupin has entered into an agreement to license cell line technology from the Australian private speciality life science firm NeuClone, as the Indian company gears up for expansion in the biologics market.